GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus rating of “Moderate Buy” by the fifteen analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.38.

A number of research firms have recently commented on GDRX. Morgan Stanley cut their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Barclays cut their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Citigroup cut their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. KeyCorp cut their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Mizuho began coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company.

Institutional Trading of GoodRx

Several hedge funds have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter valued at approximately $33,000. Fortem Financial Group LLC grew its stake in shares of GoodRx by 7.2% in the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after buying an additional 7,996 shares during the period. XTX Topco Ltd grew its stake in shares of GoodRx by 42.4% in the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after buying an additional 8,801 shares during the period. Canada Pension Plan Investment Board grew its stake in shares of GoodRx by 5.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock valued at $1,296,000 after buying an additional 9,200 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in shares of GoodRx in the 3rd quarter valued at approximately $73,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

GDRX opened at $4.71 on Thursday. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a fifty day moving average of $4.59 and a two-hundred day moving average of $6.39. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -157.00, a PEG ratio of 2.31 and a beta of 1.27.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.